The global blood culture tests market size was valued at over USD 3.7 billion in 2018 and is anticipated to expand at a CAGR of 9.1% over the forecast period. Growing approval rate of new products, such as instruments and consumables for Bloodstream Infections (BSI) diagnosis, by regulatory authorities is a major factor contributing to the growth.
Blood culture tests play a vital role in the diagnosis of bacterial, fungal, and mycobacterial among other infections. Various techniques, including conventional/manual and automated blood culture methods, are used by healthcare professionals for the detection of infection. Thus, the demand is expected to rise in the near future.
Rising prevalence of infectious diseases, BSIs, and sepsis are expected to be the main factor driving market growth. According to the World Health Organization (WHO), about 250,000 cases of BSIs occur in the U.S. annually, and among them, around 80,000 patients in ICUs suffer from catheter-related BSIs. As a result, there is a high demand for advanced products by hospitals and clinical diagnostics laboratories for the detection of bacterial, fungal, and mycobacterial infections.
There has been an increase in R&D activities by many healthcare companies to develop advanced products such as instruments, consumables, and software. Investment on R&D for the development of novel product is a crucial strategy of vendors to support long-term growth of their businesses. For instance, Becton, Dickinson and Company, a leading blood culture testing product provider, invested around USD 1,430 million in R&D in 2016.
Stringent government regulations for the development and manufacturing of diagnostic products, including blood culture tests products, could hinder the market growth. The diagnostic products, such as instruments, kits, reagents, media, and assays, undergo rigorous clinical trials prior to a regulatory approval. This leads to a significant rise in the costs incurred by the manufacturers and delay in product launch. The commercialization of diagnostic products depends on the successful completion of clinical trials, which is a long, uncertain, and costly process. In addition, product recall is another major challenge faced by manufacturers, which could adversely affect the growth.
In 2018, consumables was the largest revenue generating segment of the blood culture tests market, due to rising application of products, such as blood culture media, assay, kits, and reagents, and other accessories, for diagnostics applications. In addition, repetitive purchase of consumables is another major driver boosting the segment growth.
The instruments segment is expected to witness significant CAGR during the forecast period due to product advancements. The automated systems, incubators, colony counters, microscopes, and gram strainers are widely used by hospitals and other diagnostic laboratories.
Diagnostics companies are focused on developing advance products to cater to the needs of their customers. For instance, in July 2014, bioMérieux, a leading diagnostics company, announced the CE mark attainment by its product VIRTUO-an advanced system for continuous monitoring of blood culture for microbial detection.
The demand for advanced blood culture testing products is high due to increasing prevalence of BSI and infectious diseases. Advanced automated systems provide fast results, minimize contamination risk, and deliver highly reliable results.
On the basis of technique, the market is bifurcated into conventional and automated. Conventional technique was the highest revenue-grossing segment in 2018 due to its extensive use by hospitals, independent clinical laboratories, and pathology laboratories.
The automated blood culture technique segment is expected to showcase the highest CAGR during the forecast period, due to the technological advancements, such as faster and precise results, and rising investments on R&D by manufacturers for new product development.
The companies are focused on launching advanced instruments and consumables to provide highly reliable and efficient tests to their customers. For instance, in June 2014, Becton, Dickinson and Company launched the BD BACTEC FX40 Blood Culture System along with the BD EpiCenter Microbiology Data Management System.
U.S., Germany, France, U.K., China, Japan, and India are expected to account for a high market share. Increasing prevalence of infectious diseases, the presence of a large number of diagnostics companies, and availability of a well-developed healthcare infrastructure are some of the factors that are anticipated to contribute to the growth.
Based on technology, the market is segmented into culture-based, molecular, and proteomic. In 2018, culture-based technology segment held the largest market share in terms of revenue. This is due to high usage of this technology by various laboratories such as hospital, reference, pathology, and physician office laboratories.
Molecular technology segment is expected to register the highest CAGR during the forecast period. Increasing investment on R&D by manufactures and increase in the incidence of infectious diseases has led to demand for rapid diagnostic techniques for detecting the presence of bacterial or fungal infection in blood.
Increasing demand for advanced diagnostic technologies, such as microarray, Polymerase Chain Reaction (PCR), and Peptide Nucleic Acid—Fluorescent In Situ Hybridization (PNA-FISH), is expected to propel the market growth. The PNA-FISH technology sub-segment is expected to register the highest CAGR during forecast period owing to its advantages, such as higher accuracy, reduced test time, and higher specificity in tests.
Developing healthcare infrastructure and rising disposable income in Asia Pacific and MEA region have spurred the demand for blood culture tests. In addition, increasing government initiatives to provide better quality healthcare facility coupled with easy availability advanced technologies is expected to boost the application of these tests.
Blood culture tests are used to detect bacterial infection that spreads into the blood in various conditions, such as osteomyelitis, meningitis, pneumonia, kidney infection, and sepsis. They can also detect fungal and mycobacterial infections. Bacterial infections segment held the leading market share in terms of revenue in 2018, as bacterial infection is the most common cause of BSI and other infections. The segment is also expected to register the highest CAGR during the forecast period.
Increasing healthcare awareness and improving healthcare infrastructure in developing countries, such as South Africa, Tanzania, China, India, and Argentina is expected to propel the segment growth. The governments of these countries are making efforts to provide better quality healthcare facilities and diagnostic products, which further supports the adoption.
The fungal infections segment is projected to witness lucrative growth over the study period owing to the prevalence of BSIs and rising number of sepsis cases worldwide. For instance, Candida species are predominant agents of fungal sepsis, which accounts for around 10% to 15% of healthcare-related infections.
In 2018, hospital laboratories accounted for the largest market share in terms of revenue. This is owing to the increasing incidence of Hospital-acquired Infections (HAIs). According to the WHO, the rate of ICU-acquired infections, including Urinary Tract Infections (UTIs) and surgical-site wound infections, is around two to three times higher in developing countries as compared to developed countries. In Canada, about 8,000 patients die annually because of hospital-acquired infections.
In addition, the hospital laboratory segment is expected to expand at the fastest CAGR over the forecast period. Rising healthcare awareness along with initiatives by the government and non-government organizations to prevent and control infectious diseases is the main factor responsible for the growth. For instance, the Centers for Disease Control and Prevention (CDC) collaborated with the government of South Africa to develop national HIV clinical and research guidelines, support HIV and TB programs, and conduct epidemiology training.
The reference laboratories segment is projected to showcase lucrative growth over the forecast period owing to increase in outsourcing of blood culture tests by hospitals to reference laboratories. The reference laboratories are equipped with novel and advanced diagnostic techniques, which provide more accurate, reliable, and fast result.
The other end use segments are academic research laboratories, bacteriological laboratories, pathology laboratories, and physician office laboratories. This segment is also projected to grow at significant pace during the forecast period.
North America held the leading market share in terms of revenue in 2018, due to the presence of many large healthcare companies such as Becton, Dickinson and Company; bioMérieux SA; Thermo Fisher Scientific, Inc.; and Roche Diagnostics.
Growth of Europe market is anticipated to be driven by availability of advanced diagnostics products and presence of highly developed healthcare infrastructure in the European countries like Germany, the U.K., Switzerland, and France. Also, growing investments in R&D by manufactures for new product development are expected to propel the growth.
Asia Pacific is projected to witness the highest CAGR during the forecast period due to high prevalence of infectious diseases and developing healthcare infrastructure. Many diagnostic companies are targeting Asian countries, such as China and India, for business expansion. The presence of large base of target population and increasing disposable income in Asia Pacific are some of the key factors contributing to the regional market growth.
Some of the key players operating in the market are Becton, Dickinson and Company; bioMérieux SA; Thermo Fisher Scientific, Inc.; Danaher Corporation; Luminex Corporation; Roche; BrU.K.er Corporation; and Abbott Laboratories. Major companies are undertaking various strategic initiatives including mergers and acquisitions, collaborations, new product development and launch, and regional expansions for serving the unmet customer needs.
The leading manufacturers such as Becton, Dickinson and Company; Roche Diagnostics, and Thermo Fisher Scientific, Inc. provide a broad range of advanced blood culture test products through their strong global distribution channel. It has led to intense competition amongst manufacturers, which is expected to affect the profit margin of vendors.
Mergers and acquisitions help the manufacturers expand their existing product portfolio along with geographical reach. For instance, in June 2016, Luminex Corporation completed the acquisition of Nanosphere, Inc. to strengthen their molecular microbiology and diagnostics businesses.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Japan, India, China, South Korea, Singapore, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global blood culture tests market report on the basis of product, technique, technology, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Blood Culture Media
Assay, Kits, and Reagents
Blood Culture Accessories
Automated Blood Culture Systems
Software & Services
Technique Outlook (Revenue, USD Million, 2015 - 2026)
Technology Outlook (Revenue, USD Million, 2015 - 2026)
Application Outlook (Revenue, USD Million, 2015 - 2026)
End-Use Outlook (Revenue, USD Million, 2015 - 2026)
Regional Outlook (Revenue, USD Million, 2015 - 2026)
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.